Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JANUARY 13, 2005 FBO #1144
SPECIAL NOTICE

A -- Indolicidin Derivatives: Potent Inhibitors of HIV-1 Integrase For Treatment of Retroviral Infection and HIV

Notice Date
1/11/2005
 
Notice Type
Special Notice
 
NAICS
541710 — Research and Development in the Physical, Engineering, and Life Sciences
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
 
ZIP Code
21702
 
Solicitation Number
Reference-Number-SF-INDO-01
 
Description
The National Cancer Institute (NCI) seeks a Cooperative Research and Development Agreement (CRADA) collaborator to develop a series of short peptides derived from indolicidin. These peptides exhibit potent anti-retroviral activity by inhibiting HIV-1 integrase and possess higher antiviral and anti-integrase activity than indolicidin itself. Potential Commercial Applications: Treatment of retroviral infections such as AIDS. These compounds may be used alone, or in combination with other anti-viral therapies directed at other viral targets such as protease and reverse transcriptase. Main Advantages of the Technology: Potential for high clinical utility since HIV-1 integrase is essential for viral replication and no counterpart exists in mammalian cells. Current State of Development: Testing of tetrameric peptides show that these oligomers inhibit the action of integrase at nanomolar concentrations. Further R&D Required: Enhancing the transport properties of the current agents Evaluating toxicology and efficacy in vivo. Patent Status: Three U.S. Patent Applications filed 1/06/2004, 2/25/2004, and 8/10/2004 Pertinent References: Krajewski K, et al. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8. Krajewski K, et al. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3203-5. Contact Information: CRADA Contact: Steven C. Fausch, Ph.D., Technology Transfer Branch, NCI Phone: 301-846-5222; E-mail: fauschs@mail.nih.gov Licensing Contact: Sally Hu, Ph.D., M.B.A., Office of Technology Transfer, NIH Phone: 301-435-5606; E-mail: hus@mail.nih.gov
 
Record
SN00732863-W 20050113/050111211632 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.